Session 5: Cell Culture: Discovery to Commercialization
Monday, July 21, 2014: 1:00 PM-4:30 PM
Regency Ballroom AB, Second Floor (St. Louis Hyatt Regency at the Arch)
Conveners:
Tiffany D. Rau - Eli Lilly and Company, 5777 Calle Tartak, 702 Carolina, PR 00979, Lake Charles, LA and Bruno Figueroa - Pfizer, ,
The path from discovery to commercialization is often long and full of opportunities and challenges. This session will focus on different approaches that industry is currently leveraging to go from discovery to commercialization “faster” such as High-throughput Research and Development, Design of Experiments and Quality by Design (QbD) to name a few. When one implements new practices and ideas there is a need for new/modified equipment sets as well as data mining and analysis tools and these topics will also be explored.


1:30 PM
S24
AMBR™ 48 AS A TOOL FOR PROCESS DEVELOPMENT AND CHARACTERIZATION FOR THE MANUFACTURE OF A BIOSIMILAR IN CHO CELLS
Matthew Zustiak, Stephanie Chakravarty, John Fondren and Matt Caple, Cell Culture Development, Gallus Biopharmaceuticals, St. Louis, MO
2:00 PM
S25
Rapid process development post clone selection to clinical production
Matthew Zustiak, Nick Sullivan, Matt Warner and Matt Caple, Cell Culture Development, Gallus Biopharmaceuticals, St. Louis, MO
3:30 PM
S27
Conversion of a fed-batch process in wave bags to the Xcellerex single-use bioreactor system using PER.C6 cells
Samira Shore, Michelle Moody, Shaun Eckerle and Matt Caple, Cell Culture Development, Gallus Biopharmaceuticals, St. Louis, MO
4:00 PM
S28
Raman yields continuous, in situ measurement and control of bioprocesses in real time.
Maryann E. Cuellar, Kaiser Optical Systems, Inc, Ann Arbor, MI
See more of: Invited Oral Papers